(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin...
Stats | |
---|---|
Dagens volum | 4 951.00 |
Gjennomsnittsvolum | 30 523.00 |
Markedsverdi | 0.00 |
EPS | $0 ( 2022-04-11 ) |
Last Dividend | $0.104 ( 2021-02-24 ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.35 |
ATR14 | $0.324 (12.13%) |
Volum Korrelasjon
Biofrontera AG Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
SOHU | 0.914 |
CHB | 0.904 |
NWL | 0.904 |
CSSEP | 0.903 |
TSRI | 0.902 |
AOUT | 0.902 |
HPK | 0.9 |
BMRA | 0.897 |
MODV | 0.897 |
OGI | 0.895 |
10 Mest negative korrelasjoner | |
---|---|
APXI | -0.914 |
WINV | -0.908 |
FRSG | -0.907 |
KAII | -0.906 |
ZEUS | -0.906 |
MLAI | -0.905 |
MATW | -0.904 |
ALSA | -0.904 |
MSAC | -0.903 |
PTOC | -0.903 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Biofrontera AG Korrelasjon - Valuta/Råvare
Biofrontera AG Økonomi
Annual | 2020 |
Omsetning: | $30.35M |
Bruttogevinst: | $26.81M (88.35 %) |
EPS: | $-0.467 |
FY | 2020 |
Omsetning: | $30.35M |
Bruttogevinst: | $26.81M (88.35 %) |
EPS: | $-0.467 |
FY | 2019 |
Omsetning: | $31.27M |
Bruttogevinst: | $26.39M (84.41 %) |
EPS: | $-0.312 |
FY | 2018 |
Omsetning: | $21.11M |
Bruttogevinst: | $16.66M (78.91 %) |
EPS: | $-0.389 |
Financial Reports:
No articles found.
Biofrontera AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0221 | 2020-03-18 |
Last Dividend | $0.104 | 2021-02-24 |
Next Dividend | $0 | N/A |
Payout Date | 2021-03-04 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.126 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 0.6 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2020 | $0.0221 | 0.22% |
2021 | $0.104 | 1.30% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.429 | 1.500 | -8.58 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.231 | 1.200 | -7.70 | -9.24 | [0 - 0.3] |
returnOnEquityTTM | -1.503 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.48 | 0.800 | 0.0937 | 0.0750 | [0.8 - 2.5] |
cashRatioTTM | 1.997 | 1.500 | 0.0174 | 0.0262 | [0.2 - 2] |
debtRatioTTM | 0.423 | -1.500 | 2.94 | -4.42 | [0 - 0.6] |
interestCoverageTTM | -2.47 | 1.000 | -2.03 | -2.03 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.102 | 2.00 | -0.0341 | -0.0683 | [0 - 30] |
freeCashFlowPerShareTTM | -0.130 | 2.00 | -0.0651 | -0.130 | [0 - 20] |
debtEquityRatioTTM | 3.24 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.883 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.251 | 1.000 | -7.02 | -7.02 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.119 | 1.000 | -1.774 | -1.774 | [0.2 - 2] |
assetTurnoverTTM | 0.538 | 0.800 | 9.75 | 7.80 | [0.5 - 2] |
Total Score | -0.244 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.33 | 1.000 | -0.640 | 0 | [1 - 100] |
returnOnEquityTTM | -1.503 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.130 | 2.00 | -0.0434 | -0.130 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.102 | 2.00 | -0.0341 | -0.0683 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -2.28 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0939 | 1.000 | -4.85 | 0 | [0.1 - 0.5] |
Total Score | -2.56 |
Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.